Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas J Mercuro

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Current Infectious Disease Reports|August 25, 2020
Clinical Utility of Lefamulin: If Not Now, When?Nicholas J Mercuro, Michael P Veve
International Journal of Antimicrobial Agents|December 29, 2017
Retrospective analysis comparing oral stepdown therapy for enterobacteriaceae bloodstream infections: fluoroquinolones versus β-lactamsNicholas J Mercuro, Patricia Stogsdill, Minkey Wungwattana
Jac-Antimicrobial Resistance|October 5, 2022
Predictors of discordant MRSA nares and respiratory cultures in patients with pneumoniaNicholas P Palisano, Christina F Yen, Nicholas J Mercuro
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 17, 2018
Ambulatory Quinolone Prescribing: Moving From Opportunity to ImplementationNicholas J Mercuro, Rachel M Kenney, Odaliz Abreu-Lanfranco, et al.
Expert Opinion on Pharmacotherapy|June 8, 2018
Combatting resistant enterococcal infections: a pharmacotherapy reviewNicholas J Mercuro, Susan L Davis, Marcus J Zervos, et al.
Frontiers in Medicine|May 30, 2024
Case report: Successful treatment of OXA-23 <i>Acinetobacter baumannii</i> neurosurgical infection and meningitis with sulbactam-durlobactam combination therapyJacob W Snowdin, Nicholas J Mercuro, Michael P Madaio, et al.
Journal of Cardiothoracic and Vascular Anesthesia|March 1, 2022
Pharmacokinetics of Cefazolin in Patients With Obesity Undergoing Surgery Requiring Cardiopulmonary BypassJustin Poltak, Christopher Connors, Minkey Wungwattana, et al.
Open Forum Infectious Diseases|July 25, 2022
Prevalence and Predictors of <i>Pseudomonas aeruginosa</i> Among Hospitalized Patients With Diabetic Foot InfectionsMichael P Veve, Nicholas J Mercuro, Ryan J Sangiovanni, et al.
International Journal of Antimicrobial Agents|February 22, 2023
Outcomes associated with empiric cefepime for bloodstream infections caused by ceftriaxone-resistant, cefepime-susceptible Escherichia coli and Klebsiella pneumoniaeBrian E Frescas, Christopher M McCoy, James Kirby, et al.
Antimicrobial Agents and Chemotherapy|June 28, 2021
Fluoroquinolone Prescribing for Diabetic Foot Infections following an FDA Drug Safety Communication for Aortic Aneurysm RiskCatherine Li, Nicholas J Mercuro, Ryan W Chapin, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Current Infectious Disease Reports|August 25, 2020
Clinical Utility of Lefamulin: If Not Now, When?Nicholas J Mercuro, Michael P Veve
International Journal of Antimicrobial Agents|December 29, 2017
Retrospective analysis comparing oral stepdown therapy for enterobacteriaceae bloodstream infections: fluoroquinolones versus β-lactamsNicholas J Mercuro, Patricia Stogsdill, Minkey Wungwattana
Jac-Antimicrobial Resistance|October 5, 2022
Predictors of discordant MRSA nares and respiratory cultures in patients with pneumoniaNicholas P Palisano, Christina F Yen, Nicholas J Mercuro
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 17, 2018
Ambulatory Quinolone Prescribing: Moving From Opportunity to ImplementationNicholas J Mercuro, Rachel M Kenney, Odaliz Abreu-Lanfranco, et al.
Expert Opinion on Pharmacotherapy|June 8, 2018
Combatting resistant enterococcal infections: a pharmacotherapy reviewNicholas J Mercuro, Susan L Davis, Marcus J Zervos, et al.
Frontiers in Medicine|May 30, 2024
Case report: Successful treatment of OXA-23 <i>Acinetobacter baumannii</i> neurosurgical infection and meningitis with sulbactam-durlobactam combination therapyJacob W Snowdin, Nicholas J Mercuro, Michael P Madaio, et al.
Journal of Cardiothoracic and Vascular Anesthesia|March 1, 2022
Pharmacokinetics of Cefazolin in Patients With Obesity Undergoing Surgery Requiring Cardiopulmonary BypassJustin Poltak, Christopher Connors, Minkey Wungwattana, et al.
Open Forum Infectious Diseases|July 25, 2022
Prevalence and Predictors of <i>Pseudomonas aeruginosa</i> Among Hospitalized Patients With Diabetic Foot InfectionsMichael P Veve, Nicholas J Mercuro, Ryan J Sangiovanni, et al.
International Journal of Antimicrobial Agents|February 22, 2023
Outcomes associated with empiric cefepime for bloodstream infections caused by ceftriaxone-resistant, cefepime-susceptible Escherichia coli and Klebsiella pneumoniaeBrian E Frescas, Christopher M McCoy, James Kirby, et al.
Antimicrobial Agents and Chemotherapy|June 28, 2021
Fluoroquinolone Prescribing for Diabetic Foot Infections following an FDA Drug Safety Communication for Aortic Aneurysm RiskCatherine Li, Nicholas J Mercuro, Ryan W Chapin, et al.
Pageof 3